

March 30, 2020

Listing Department
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai – 400001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400051

Code: CADILAHC

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a Press Release dated March 30, 2020 titled “Zydus receives tentative approval from the USFDA for Carbidopa and Levodopa Extended-Release Capsules”.

The contents of the Press Release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and investors’ at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

sd/-

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus receives tentative approval from the USFDA for Carbidopa and Levodopa Extended-Release Capsules

Ahmedabad, March 30, 2020

Zydus Cadila has received tentative approval from the USFDA to market Carbidopa and Levodopa Extended-Release Capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg. (US RLD: Rytary®)

This combination medication is indicated for the treatment of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, and difficulty moving) and will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has 282 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
